相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。PQ Interval in Patients With Fabry Disease
Mehdi Namdar et al.
AMERICAN JOURNAL OF CARDIOLOGY (2010)
A detailed pathologic examination of heart tissue from three older patients with Anderson-Fabry disease on enzyme replacement therapy
Mary N. Sheppard et al.
CARDIOVASCULAR PATHOLOGY (2010)
Evidence for a role of sphingosine-1 phosphate in cardiovascular remodelling in Fabry disease
Noureddine Brakch et al.
EUROPEAN HEART JOURNAL (2010)
Cardiovascular manifestations of Fabry disease: relationships between left ventricular hypertrophy, disease severity, and α-galactosidase A activity
Justina C. Wu et al.
EUROPEAN HEART JOURNAL (2010)
Fabry disease: a review of current management strategies
A. Mehta et al.
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE (2010)
Long-Term Effects of Enzyme Replacement Therapy on Fabry Cardiomyopathy Evidence for a Better Outcome With Early Treatment
Frank Weidemann et al.
CIRCULATION (2009)
Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa
D. A. Hughes et al.
HEART (2008)
Cardiovascular testing in Fabry disease: exercise capacity reduction, chronotropic incompetence and improved anaerobic threshold after enzyme replacement
T. Lobo et al.
INTERNAL MEDICINE JOURNAL (2008)
Cardiac manifestations of Anderson-Fabry disease results from the international Fabry outcome survey
Ales Linhart et al.
EUROPEAN HEART JOURNAL (2007)
Heart in Anderson-Fabry disease and other lysosomal storage disorders
Ales Linhart et al.
HEART (2007)
Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy
Meinrad Beer et al.
AMERICAN JOURNAL OF CARDIOLOGY (2006)
The Mainz Severity Score Index (MSSI): development and validation of a system for scoring the signs and symptoms of Fabry disease
M Beck
ACTA PAEDIATRICA (2006)
Recommendations for chamber quantification: A report from the American Society of Echocardiography's guidelines and standards committee and the chamber quantification writing group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology
RM Lang et al.
JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY (2005)
Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease
JS Shah et al.
AMERICAN JOURNAL OF CARDIOLOGY (2005)
Enzyme replacement therapy in heterozygous females with Fabry disease: Results of a phase IIIB study
F Baehner et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2003)
Fabry disease: a functional and anatomical study of cardiac manifestations in 20 hemizygous male patients
M Senechal et al.
CLINICAL GENETICS (2003)
Safety and efficacy of recombinant human α-galactosidase a replacement therapy in Fabry's disease.
CM Eng et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Enzyme replacement therapy in Fabry disease - A randomized controlled trial
R Schiffmann et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
A phase 1/2 clinical trial of enzyme replacement in Fabry disease: Pharmacokinetic, substrate clearance, and safety studies
CM Eng et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2001)
Ventricular fibrillation refractory to automatic internal cardias defibrillator in Fabry's disease - Review of cardiovascular manifestations
RE Eckart et al.
CARDIOLOGY (2000)
分享论文
